Search - tctmd.com

Displaying 441 - 460 of 1388

Sort: Relevancy | Date

Presentation TCT 2016

Echo Quantification of MR Severity: Classification and Common Pitfalls

Presenter: Paul A. Grayburn, Patrizio Lancellotti

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Brazil Presents a Case: Complex Access in TAVI the Transcaval Approach

Presenter: Rui Campante Teles, Marcelo Jose de Carvalho Cantarelli, Dimytri Alexandre Siqueira

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Aaron Chalekian

October 30, 2016

Presentation TCT 2016

Whats New and What's Controversial in the US and EU Guidelines?

Presenter: Ted Feldman, Allan Schwartz, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, John G. Webb

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Presenter: Ted Feldman, Allan Schwartz, JoAnn Lindenfeld

October 30, 2016

Presentation TCT 2016

Animal Testing: Real-World Experiences and Translational Challenges

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Presenter: Patrick T. O'Gara, Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

My Thoughts on the Radial Approach in Complex PCI

Presenter: Georgios Sianos, Christos Christou

October 30, 2016

Presentation TCT 2016

Animal Testing: FDA Expectations

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Natalie Miller

October 30, 2016

Presentation TCT 2016

Epidemiology and Treatment of Primary and Secondary Mitral Regurgitation: Global Perspectives

Presenter: Ted Feldman, Allan Schwartz, Ralph Stephan von Bardeleben

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

Advertisement

Echo Quantification of MR Severity: Classification and Common Pitfalls

Intermediate-Risk Studies II: Updates From SURTAVI

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Brazil Presents a Case: Complex Access in TAVI the Transcaval Approach

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Whats New and What's Controversial in the US and EU Guidelines?

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Animal Testing: Real-World Experiences and Translational Challenges

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Impact of LAA Exclusion on Neurohormonal Modulation

My Thoughts on the Radial Approach in Complex PCI

Animal Testing: FDA Expectations

Epidemiology and Treatment of Primary and Secondary Mitral Regurgitation: Global Perspectives

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content